117 related articles for article (PubMed ID: 37991388)
21. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
24. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
[TBL] [Abstract][Full Text] [Related]
25. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
26. High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
Roh W; Geffen Y; Cha H; Miller M; Anand S; Kim J; Heiman DI; Gainor JF; Laird PW; Cherniack AD; Ock CY; Lee SH; Getz G;
Cancer Res; 2022 Nov; 82(21):3917-3931. PubMed ID: 36040373
[TBL] [Abstract][Full Text] [Related]
27. [Clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
[No Abstract] [Full Text] [Related]
28. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
29. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.
Malkoski SP; Haeger SM; Cleaver TG; Rodriguez KJ; Li H; Lu SL; Feser WJ; Barón AE; Merrick D; Lighthall JG; Ijichi H; Franklin W; Wang XJ
Clin Cancer Res; 2012 Apr; 18(8):2173-83. PubMed ID: 22399565
[TBL] [Abstract][Full Text] [Related]
30. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
31. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
32. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
33. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract][Full Text] [Related]
34. Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung.
He SY; Xi WJ; Wang X; Xu CH; Cheng L; Liu SY; Meng QQ; Li B; Wang Y; Shi HB; Wang HJ; Wang ZZ
Med Sci Monit; 2019 May; 25():3941-3956. PubMed ID: 31132294
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
[TBL] [Abstract][Full Text] [Related]
36. Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile.
Deng S; Lu X; Zhang Z; Meng R; Li M; Xia S
J Cell Mol Med; 2021 Jul; 25(14):6652-6663. PubMed ID: 34080290
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Daemen A; Cooper JE; Myrta S; Wongchenko MJ; Lin E; Long JE; Foreman O; Modrusan Z; Tremayne JR; de la Cruz CC; Merchant M; Martin SE; Yan Y; Junttila MR
Clin Cancer Res; 2021 Feb; 27(4):1162-1173. PubMed ID: 33023953
[TBL] [Abstract][Full Text] [Related]
38. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB
Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259
[TBL] [Abstract][Full Text] [Related]
40. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
